Cryptococcus neoformans is a fungus found in soil and bird droppings worldwide that primarily threatens people with weakened immune systems, especially those living with advanced HIV/AIDS. Infection begins when someone inhales microscopic fungal cells, which can then spread from the lungs to the brain, causing a life-threatening form of meningitis. The fungus has evolved a remarkable set of biological tools to survive inside the human body, and treatment typically requires potent antifungal drugs given in carefully staged phases over many months.
Where the Fungus Lives and How People Get Infected
C. neoformans thrives in environments enriched with bird droppings, particularly pigeon excreta, but it also inhabits decaying wood and the hollows of certain trees. In one survey of environmental samples from Tripoli, Libya, the fungus was isolated from pigeon droppings and from the bark of eucalyptus and olive trees, confirming that urban environments with bird populations serve as significant reservoirs.1PubMed. Isolation, Identification and Molecular Typing of Cryptococcus neoformans from Pigeon Droppings and Other Environmental Sources in Tripoli, Libya The fungal cells in dried droppings become small enough to be carried on air currents and inhaled deep into the lungs. You do not catch it from another person. There is no human-to-human transmission under normal circumstances.
Most healthy people who inhale C. neoformans never become sick. Their immune systems either clear the fungus or contain it in a dormant state within the lungs, sometimes for years. The trouble starts when the immune system falters, allowing the fungus to reactivate and spread.
Who Is at Risk
The single biggest risk factor is advanced HIV infection. Cryptococcal disease emerged as a major killer during the HIV pandemic, predominantly striking patients with severely depleted T-cell counts.2PubMed Central. Host immunity to Cryptococcus neoformans In sub-Saharan Africa, cryptococcal meningitis remains one of the leading causes of death among people living with HIV. Other groups at elevated risk include organ transplant recipients on immunosuppressive drugs, people on long-term corticosteroid therapy, and individuals with certain blood cancers. In a large international cohort study, about four in five patients with cryptococcosis had some underlying condition, and HIV and solid organ transplantation were among the most common.3Clinical Infectious Diseases. MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections
Occasionally, people with no identifiable immune deficiency develop cryptococcal disease. These cases tend to be milder and more often confined to the lungs, but they do occur and can be puzzling for clinicians. One published case described a 55-year-old man with no known medical problems who developed cryptococcal meningitis with persistent elevated brain pressure despite standard treatment.4PubMed Central. Persistent neurological symptoms and elevated intracranial pressures in a previously healthy host with cryptococcal meningitis
How the Fungus Survives Inside You
C. neoformans is unusually well-equipped to evade your immune defenses, and this is a big part of why it is so dangerous compared to other fungi you might inhale. It relies on several biological tricks that work together.
The most distinctive is its polysaccharide capsule, a thick, slimy outer coat that surrounds the fungal cell. This capsule blocks immune cells from engulfing the fungus and absorbs the chemical attacks those cells launch.5PubMed Central. The capsule of Cryptococcus neoformans It is so effective that strains lacking a capsule are essentially harmless in animal experiments.
The fungus also produces melanin, a dark pigment made with the help of an enzyme called laccase. Melanin shields the cell against the toxic molecules immune cells use to kill pathogens. Mutant strains that cannot make melanin are far more vulnerable to killing by nitrogen- and oxygen-based radicals and are significantly less virulent in mice.6PubMed Central. Cryptococcus neoformans melanin and virulence: mechanism of action Lab experiments have confirmed that melanin also protects the fungus against certain antibiotics and makes the cells harder for immune cells to swallow.7FEMS Yeast Research. Role of laccase in the biology and virulence of Cryptococcus neoformans
Another key advantage is thermotolerance. While many environmental fungi cannot grow at human body temperature, C. neoformans thrives at 37°C and can tolerate even higher fevers. This ability involves complex internal reprogramming. During a temperature shift, the fungus ramps up production of heat shock proteins and chaperones while suppressing other processes, and it can mask cell-surface molecules that would otherwise alert immune cells to its presence.8PubMed Central. Thermotolerance in the pathogen Cryptococcus neoformans is linked to antigen masking via mRNA decay-dependent reprogramming
Titan Cells and Their Role in Disease
One of the more striking things C. neoformans can do inside the body is dramatically enlarge itself. Normal cells measure roughly 5 to 7 micrometers across. Inside the lungs, some cells balloon to 50 or even 100 micrometers in diameter, earning the name “titan cells.”9PubMed Central. Titan cells in Cryptococcus neoformans: cells with a giant impact At that size, they are simply too large for immune cells to engulf. Titan cells also have altered cell wall composition, with increased chitin content compared to normal-sized cells.10The Cell Surface. Titan cell production in Cryptococcus neoformans reshapes the cell wall and capsule composition during infection
Animal studies show that titan cell formation directly increases virulence. A mutant strain that produced very few titan cells caused less severe disease, had lower fungal counts in the lungs, and was less likely to spread to other organs than the normal strain. The titan cell-producing strain also shifted the immune response in the lungs, drawing in more eosinophils and reducing the proportion of fungal cells that were successfully engulfed and killed.11PubMed Central. Titan cell production enhances the virulence of Cryptococcus neoformans
How It Reaches the Brain
The most feared complication of C. neoformans infection is meningoencephalitis, inflammation of the brain and its surrounding membranes. Getting to the brain requires crossing the blood-brain barrier, a tightly sealed layer of cells that normally keeps pathogens out. C. neoformans appears to use at least two routes. It can directly invade the barrier cells by hijacking a receptor on the surface of brain blood vessel cells, triggering those cells to internalize it.12PubMed Central. The Human Blood-Brain Barrier Internalizes Cryptococcus neoformans via the EphA2-Tyrosine Kinase Receptor
It also exploits a “Trojan horse” strategy. Immune cells called macrophages engulf the fungus in the lungs, but instead of dying inside those cells, C. neoformans survives and hitches a ride as the macrophage crosses the blood-brain barrier. Researchers have directly imaged these fungus-laden immune cells squeezing through the barrier via temporary pores. This Trojan horse route is so effective that certain fungal mutants that cannot cross the barrier on their own can still reach the brain inside macrophages.13PubMed Central. Trojan Horse Transit Contributes to Blood-Brain Barrier Crossing of a Eukaryotic Pathogen
Symptoms of Cryptococcal Disease
The clinical picture depends heavily on where in the body the fungus takes hold and how weakened the immune system is. There are three broad patterns.
Lung Infection
Pulmonary cryptococcosis often starts with cough, which was present in about 83% of patients in one clinical series.14PubMed. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients Chest imaging typically shows pulmonary nodules, often multiple and small, with a tendency to sit in the periphery of the lungs.15PubMed. Pulmonary cryptococcosis: CT findings in immunocompetent patients In people with healthy immune systems, the nodules are usually well-defined with smooth borders and cavitation is less common. Immunocompromised patients are more likely to have cavitation within nodules and areas of lung consolidation.16PubMed. Pulmonary cryptococcosis in immunocompetent patients: CT findings in 12 patients In mild cases, some people have no symptoms at all and the infection is only discovered incidentally on imaging done for another reason.
Brain and Meningeal Infection
Cryptococcal meningoencephalitis is the most common life-threatening presentation, particularly in HIV-positive patients. Symptoms build over days to weeks and typically include worsening headache, confusion, and changes in mental function. Fever is not always present. One of the hallmarks is elevated intracranial pressure, driven by a heavy fungal burden clogging the fluid drainage pathways around the brain.17PubMed Central. Elevated Intracranial Pressure in Cryptococcal Meningoencephalitis: Examining Old, New, and Promising Drug Therapies This pressure can cause nausea, vomiting, vision changes, and if untreated, coma and death.
Skin and Disseminated Disease
When the fungus spreads through the bloodstream, it can seed virtually any organ including the kidneys, bones, and skin.18Journal of Mycology and Infection. Cutaneous Manifestation of Disseminated Cryptococcosis Mimicking Herpes Zoster Skin lesions appear in a meaningful fraction of disseminated cases, and they may be the first sign that something is wrong. In a systematic review of cutaneous cryptococcosis in kidney transplant recipients, about two thirds of patients had disseminated disease, and skin lesions were the initial clue in roughly 70% of those cases.19PubMed. Cellulitis-like cutaneous cryptococcosis revealing disseminated infection in a kidney transplant recipient: a case report and systematic review The lesions can look like almost anything: papules, nodules, ulcers, or areas that resemble cellulitis or even herpes. This variability makes skin cryptococcosis easy to misdiagnose, so clinicians treating immunocompromised patients learn to biopsy unexplained skin lesions.
Diagnosis
The fastest and most widely used test for cryptococcal meningitis is a lateral flow assay that detects cryptococcal antigen in blood or spinal fluid. In one diagnostic accuracy study, this rapid test showed strong sensitivity and specificity, making it a reliable point-of-care option, especially in resource-limited settings where more complex tests may not be available.20PubMed Central. Diagnostic Accuracy of Cryptococcal Antigen Lateral Flow Assay Compared With Microscopy and Culture in Suspected Cryptococcal Meningitis The test produces a result within minutes from a drop of blood or spinal fluid.
Traditional microscopy using India ink staining of spinal fluid can visualize the fungus directly by highlighting the capsule’s halo, but this method catches only about 63% of cases.20PubMed Central. Diagnostic Accuracy of Cryptococcal Antigen Lateral Flow Assay Compared With Microscopy and Culture in Suspected Cryptococcal Meningitis It is highly specific (a positive result is almost certainly correct), but a negative result does not rule out the disease. Fungal culture remains the gold standard for definitive identification but takes days to grow.
Treatment
Treating cryptococcal meningitis follows a phased approach: an aggressive induction phase to drive down the fungal load, followed by longer consolidation and maintenance phases to keep the infection from returning. The Infectious Diseases Society of America guidelines emphasize three principles: using a fungicidal induction regimen (typically a polyene antifungal combined with flucytosine), managing elevated intracranial pressure early, and switching to lipid formulations of amphotericin B when kidney damage is a concern.21PubMed Central. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america
A major advance in recent years has been the AMBITION trial, which showed that a single high dose of liposomal amphotericin B (given intravenously at 10 mg/kg) combined with two weeks of oral flucytosine and fluconazole was noninferior to the older standard of daily amphotericin infusions for a week. Ten-week mortality was about 25% in the single-dose group compared to about 29% in the control group, and the single-dose group had fewer serious side effects.22PubMed Central. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis This is a significant practical improvement because daily amphotericin infusions require hospitalization, careful monitoring of kidney function, and nursing resources that many hospitals in high-burden countries struggle to provide.
Early real-world adoption of the single-dose protocol has shown promise. At a US public hospital that transitioned to this approach for HIV-associated cryptococcal meningitis, 90-day mortality was 4% in the intervention group compared to 10% in the historical control group, though the study was small and the difference was not statistically significant.23JAMA Network Open. Single-Dose Liposomal Amphotericin Plus Fluconazole and Flucytosine for Cryptococcal Meningitis at a US Public Hospital After induction, patients step down to oral fluconazole alone for a consolidation period of about eight weeks, then continue a lower maintenance dose for a year or longer, particularly if the underlying immune deficiency persists.
Managing Elevated Brain Pressure
Elevated intracranial pressure is both the most dangerous acute complication of cryptococcal meningitis and, frustratingly, one that antifungal drugs alone do not reliably fix. The mechanism appears to involve fungal cells physically obstructing the normal drainage pathways of cerebrospinal fluid, creating a backup of pressure.24PubMed Central. Pathophysiology of intracranial hypertension in cryptococcal meningoencephalitis Patients frequently improve dramatically after draining fluid via a lumbar puncture, only to have pressure re-accumulate within hours.
The practical upshot is that many patients need repeated spinal taps, sometimes several per day, to keep the pressure under control while the antifungal drugs work on clearing the fungus. In one extreme but instructive case, a patient underwent 76 therapeutic lumbar punctures over the course of treatment, with large volumes of fluid removed each time, without serious complications from the drainage itself.25PubMed Central. Persistently elevated intracranial pressure in cryptococcal meningitis– 76 therapeutic lumbar punctures In well-resourced settings, temporary lumbar drains or permanent shunts can be placed surgically, but in many parts of the world where cryptococcal meningitis is most common, repeated lumbar punctures remain the frontline approach. Failing to manage this pressure aggressively is a major contributor to poor outcomes.
Immune Reconstitution Inflammatory Syndrome
For HIV-positive patients who start antiretroviral therapy, there is a paradoxical risk. As the immune system recovers, it can mount an overly aggressive inflammatory response against residual fungal material in the body, causing a flare of symptoms called immune reconstitution inflammatory syndrome, or IRIS. In the context of cryptococcal disease, IRIS typically shows up one to two months after beginning antiretroviral therapy, though delayed cases have been reported up to eight or nine months later.26Current Opinion in Infectious Diseases. Cryptococcal immune reconstitution inflammatory syndrome Symptoms can mimic a new infection or relapse, with worsening headache, fever, and rising intracranial pressure, even though the patient’s antifungals may be working perfectly well against the fungus itself.27The Lancet Infectious Diseases. Cryptococcal immune reconstitution inflammatory syndrome: a proposed definition
IRIS is part of the reason that clinical guidelines recommend delaying the start of antiretroviral therapy for several weeks after beginning antifungal treatment in patients with cryptococcal meningitis. Allowing the antifungals time to reduce the fungal burden before the immune system ramps back up lowers the intensity of the inflammatory response.
Fluconazole Resistance
Fluconazole is the backbone of long-term maintenance therapy and the most accessible antifungal in low-income countries. Unfortunately, C. neoformans has developed a clever mechanism to resist it. Individual strains can generate subpopulations of cells with extra copies of specific chromosomes, a phenomenon called heteroresistance. These duplicated chromosomes carry genes involved in drug efflux and in the drug’s target pathway, so having extra copies effectively dilutes fluconazole’s impact.28PubMed Central. Fluconazole Resistance and Heteroresistance in Cryptococcus spp.: Mechanisms and Implications In mouse models, these resistant subpopulations have been shown to emerge in the brain during fluconazole treatment, though the degree varies between strains.29PubMed Central. Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment
This is part of why the induction phase relies on amphotericin B and flucytosine rather than fluconazole alone. Fluconazole slows fungal growth but does not kill cells efficiently, and starting with a weaker regimen risks selecting for resistant subpopulations from the outset. Heteroresistance also helps explain why some patients relapse after months of apparently successful fluconazole maintenance.
C. neoformans Versus C. gattii
When people talk about “Cryptococcus,” they usually mean C. neoformans, but a closely related species called C. gattii causes a distinct pattern of disease. The two species tend to affect different populations and target different organs. C. neoformans overwhelmingly affects immunocompromised patients and has a strong tendency to cause brain infection. C. gattii is more often found in people without identifiable immune problems, and the infection tends to be more lung-centered.30PubMed Central. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis
Mouse studies reinforce this clinical observation: when animals were infected through inhalation, C. neoformans grew faster in the brain and caused death from meningoencephalitis, while C. gattii grew faster in the lungs and caused death by overwhelming pneumonia without fulminating brain involvement.31PubMed Central. The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model In the large international MSG07 cohort, pulmonary infection was present in about 61% of C. gattii cases but only 32% of C. neoformans cases, while brain, blood, and skin involvement were all significantly more common with C. neoformans. HIV was a factor in nearly 39% of C. neoformans patients but under 4% of C. gattii patients.3Clinical Infectious Diseases. MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With Cryptococcus neoformans or Cryptococcus gattii Infections
C. gattii gained public attention during an outbreak on Vancouver Island beginning in the late 1990s that then spread to the Pacific Northwest of the United States, affecting seemingly healthy individuals. That outbreak was a reminder that not all cryptococcal disease is tied to HIV, and it spurred research into what makes certain environments and certain people vulnerable to C. gattii. However, globally, C. neoformans remains the far more common cause of disease, responsible for the vast majority of cases and deaths.
Screening in High-Risk Populations
Because cryptococcal meningitis is so deadly yet potentially preventable with early antifungal treatment, researchers have explored screening programs for people with advanced HIV. The idea is straightforward: test people with very low CD4 counts for cryptococcal antigen in the blood before they develop symptoms, and treat those who test positive with preemptive fluconazole. One cluster-randomized trial of this “screen-and-treat” approach in HIV-positive patients with CD4 counts below 100 found no clear survival benefit from the intervention, though the study’s design may have diluted the effect.32PubMed Central. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial Despite the mixed trial data, the World Health Organization has recommended cryptococcal antigen screening for people with advanced HIV, reasoning that the low cost of the test and the high stakes of missed cases tip the balance in favor of screening, especially in regions where cryptococcal meningitis mortality remains staggeringly high.